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ABSTRACT 
Aberrant amyloid-β peptide (Aβ) accumulation along with altered expression and 
function of nicotinic acetylcholine receptors (nAChRs) stand prominently in the etiology of 
Alzheimer’s disease (AD).   Since the discovery that Aβ is bound to α7 nAChRs under many 
experimental settings, including post-mortem AD brain, much effort has been expended to 
understand the implications of this interaction in the disease milieu.  This research update will 
review the current literature on the α7 nAChR – Aβ interaction in vitro and in vivo, the 
functional consequences of this interaction from sub-cellular to cognitive levels, and discuss the 
implications these relationships might have for AD therapies. 
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1. INTRODUCTION 
Alzheimer’s disease (AD) is marked by selective cholinergic denervation of the cerebral cortex 
which is most severe in the temporal lobes and the adjacent limbic and paralimbic areas.  The 
hippocampus is a particularly early and vulnerable target of the disease.  These neocortical 
cholinergic pathways are critical for the modulation of attention and memory; as such, the AD 
cholinergic lesion manifests as episodic memory impairment (1-4).  The clinical observations 
that cholinomimetics induce symptomatic improvement in AD and the correlation between the 
magnitude of cholinergic depletion and the severity of  dementia provides clinical evidence for 
the relevance of the cholinergic lesion to the clinical features of AD (5-8).  
The basal forebrain, including the medial septal nucleus, diagonal band nuclei, and 
nucleus basalis, is the major source of cholinergic input to the hippocampus and neocortex.  
The α7 subtype of nicotinic acetylcholine receptors (nAChRs) is particularly enriched in 
these cholinergic target areas; in fact, initial Aβ deposition in early AD overlap with α7 
nAChR expression in the basal forebrain cholinergic system (9, 10).  Furthermore, the 
cholinergic deficit in early AD is due in part to altered expression and function of these 
receptors (8, 11-16).  The α7 nAChRs flux the pluripotent second messenger Ca2+ and have 
been shown to modulate neuron excitability, neurotransmitter release, the induction of 
LTP, learning, and memory (17-21).   Likewise, in patients with mild to moderate AD, 
activation of this receptor improves attention, learning, and memory performance (22-26).  
Therefore α7 nAChRs are highly implicated in the etiology of early AD.   
In the decade-plus since the discovery of a high affinity interaction between Aβ peptides 
and α7 nAChRs, several investigative teams have aggressively pursued the biological relevance 
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of this interaction.  At this time, these efforts support a model in which the α7 nAChR – Aβ 
interaction performs a physiologic role since Aβ peptides are continuously produced under 
normal conditions as well as contributes to the etiology of AD as Aβ peptide concentration and 
aggregation proceed pathologically (9, 10, 27-30).  This research update will discuss the current 
literature on the α7 nAChR – Aβ interaction in vitro and in vivo, the functional consequences of 
this interaction from sub-cellular to cognitive levels, and discuss the implications these 
relationships have for AD therapies. 
2. Aβ PEPTIDES ARE CONFORMATIONALLY DYNAMIC 
In vivo generated Aβ fragments can be of different lengths and can take many forms, all 
of which may behave differently in biological systems.  Aβ in a monomeric form is relatively 
unstructured in vitro. Oligomerization (dimers, trimers, tetramers, hexamers, dodecamers, etc) 
can make the fragment more rigid while retaining its aqueous solubility.  Further aggregation of 
Aβ can create an insoluble fibril structure, which is a key component of the amyloid plaques 
found in individuals with AD.  While it is widely agreed that purely monomeric and fibrillar 
assemblies of Aβ peptide are unlikely to be the disease-relevant stoichiometries, which 
oligomeric aggregate species is responsible for the synaptic dysfunction and ultimate 
neurodegeneration in AD remains debated.   
Several lines of evidence indicate that oligomeric assemblies of Aβ possess unique 
functional properties including the ability to modulate synaptic transmission and influence 
learning and memory in an α7 nAChR-dependent manner.  For example, purified oligomers 
(dimers, trimers, as well as a 56 kDa dodecamer aggregate) of in vitro and in vivo produced Aβ 
can disrupt synaptic plasticity and cognitive function when administered at high (nanomolar) 
concentration and α7 nAChR activation can overcome LTP impairments suggesting that α7 
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nAChRs are an important target of oligomeric Aβ (31-35).  However, recent work has implicated 
very low (picomolar) concentrations of monomer, trimer, tetramer, and hexamer Aβ1-42 as 
playing a role in modulating hippocampal synaptic plasticity and enhancing cognitive function in 
mice via an α7 nAChR-dependent mechanism (36, 37).  How can one observe such conflicting 
effects of α7 nAChR – Aβ interaction?  Given that Aβ peptide structure and aggregation 
properties are dynamic and depend on concentration, pH, salinity, chelation status, and 
temperature, it is not surprising that very different results are obtained with Aβ solutions 
prepared in methodologically distinct ways.   
The work reviewed here exclusively used soluble Aβ peptides that likely represent a 
mixture of monomeric and oligomeric assemblies.  However the precise structure and 
aggregation state of the peptide solution in these studies is largely unknown, further 
confounding the interpretation of results.  Therefore, it will continue to be important to not 
only specify the concentration of soluble Aβ used, but also to specify the structural nature of 
the preparation.  This is currently becoming much more of a trend and several recent 
publications have attempted to structurally define the peptide solution (36, 38-40).  These 
efforts greatly facilitate our interpretation of investigations into the complex nature of Aβ 
peptide interaction with α7 nAChRs.  It is hoped that future work will correlate the effects of 
the Aβ – nAChR interaction with specific peptide structures; as has been formally requested in a 
recent editorial (Cole, Nature Neuroscience, 2011). 
3. α7 NACHRS AND Aβ INTERACT WITH HIGH AFFINITY IN VITRO AND IN VIVO 
An α7 nAChR – Aβ interaction was first described over a decade ago; since then many 
studies have reported seemingly incongruent consequences of this interaction emphasizing a 
complex biology that underlies this interaction.  Initial work published by Wang et al. (27, 28) 
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demonstrated that α7 nAChRs and Aβ are co-localized in AD cortical regions including the 
hippocampus; these proteins are found not only in the membrane fraction but also in amyloid 
plaque deposits.  They also demonstrated that the receptor – peptide complex could be co-
immunoprecipitated and detected with immunoblot; this was shown for both control and AD 
brain samples.  Because this association resists detergent treatment, it prompted the 
investigators to postulate that α7 nAChRs and Aβ may associate with rather high affinity, 
possibly for extended periods of time (27, 41).  As discussed in the following sections, this 
hypothesis has yet to be refuted and more recent findings indicate that Aβ-mediated 
inactivation of α7 nAChRs may be one of the detrimental aspects of this protein interaction in 
AD (9, 10, 42). 
3.1 NATURE OF Aβ BINDING TO α7 NACHRS 
The exact nature of the Aβ interaction with α7 nAChRs is not well understood.  
Computer simulated docking studies have been performed by Espinoza-Fonseca (2004) utilizing 
the homology model of the human α7 nAChR derived from the X-ray structure of the 
acetylcholine-binding protein (AChBP) and the lowest energy NMR structure of the human Aβ1-
42 peptide as well as four fragments (amino acids 1-11, 10-20, 12-28, and 22-35) (43, 44).   
These analyses were achieved using a modified version of ESCHER software that analyzes the 
complementarity of the target and probe proteins in 360o using their solvent accessible 
surfaces.  Their results indicated that the full length peptide and peptide fragments bind 
parallel to the receptor within the binding interface between two subunits.  Based on the series 
of docking studies with the full length Aβ peptide and the four fragments in complex with the 
α7 nAChR, Espinoza-Fonseca concluded that the interaction domains common amongst all five 
receptor:peptide complexes involved residues V12-K28 of Aβ1-42 and the agonist binding loop C 
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of one subunit of the receptor and a loop delineated by amino acids 62-74 and loop G of the 
adjacent subunit of the receptor.  Thus, it appears energetically favorable for monomeric Aβ1-
42 to bind components of the agonist binding site.    
To further support the strength of these studies, the fragments used in the Espanoza-
Fonseca studies correspond to the fragments identified by Wang et al. (2003) that were most 
effective in competition binding studies against cells expressing α7 nAChRs (45).  The Aβ1-42 
peptide fragments defined as interaction points with the ligand binding domain of the α7 
nAChR are common between both Aβ1-40 and Aβ1-42 suggesting that the two additional 
hydrophobic amino acids at the C-terminus of Aβ1-42 alter the conformation of the central 
hydrophilic portion of the peptide to increase binding affinity (28).      
Initial competition binding studies on membrane preparations from brain regions and 
cell lines expressing the α7 nAChR indicated that Aβ association occurred with an affinity in the 
low picomolar range while similar experiments for α4β2 nAChRs indicated an affinity 100 – 
5,000 times lower (27, 28).  The apparent affinity for the α7 nAChR – Aβ1-42 interaction and the 
fact that soluble
Curve fit analysis from binding studies on α7-expressing cells, suggested that there were 
two saturable Aβ binding sites (28).  While extensive binding studies with Aβ peptides and α7-
expressing cells have not since been published, several functional studies utilizing a variety of 
 Aβ1-42 in healthy brain and CSF has been estimated at picomolar values 
indicates that these two proteins could associate under normal physiologic conditions leading 
to receptor activation (46-48); recent behavioral and synaptic plasticity studies provide 
evidence that this is indeed the case, at least in hippocampus (36, 37).  As AD progresses Aβ 
levels exponentially increase in AD-affected brain regions, achieving nanomolar levels and, as 
discussed in later sections, likely lead to α7 nAChR inactivation (46-48). 
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preparations have pharmacologically blocked Aβ-mediated effects via α7 nAChR-selective 
antagonists such as α-bungarotoxin (BTX) and methyllycaconitine (MLA) (31, 36, 39, 49-54).  
These publications utilized Aβ1-42 preparations that were either roughly defined as ‘oligomeric’ 
or were more precisely defined as being comprised of a mixture of at least two of the following: 
monomer, dimer, trimer, and hexamer.  These data suggest that Aβ preparations that result in 
α7 nAChR activation utilize a binding site that is comprised, at least in part, by components of 
the Cys-loop inter-subunit agonist binding site.   
It should be noted that a number of those that have observed Aβ-mediated functional 
antagonism of α7 nAChRs have reported that this is noncompetitive in nature since α7 nAChR-
selective antagonists such as BTX or MLA were unable to block, or agonist was able to only 
partially overcome Aβ inhibitory effects (55-58).  These noncompetitive binding results infer 
that the Aβ preparations utilized (uncharacterized in these studies) gained access to a binding 
site distinct from the Cys-loop inter-subunit acetylcholine ligand binding pocket.   
A recently described intra-subunit allosteric binding pocket located within the 
transmembrane domain of the α7 nAChR provides a potential structure-function mechanism to 
explain noncompetitive Aβ antagonism (59-61).  In support of this model, recent work on 
heterologously expressed α4β2 and α2β2 nAChRs showed that the positive allosteric modulator 
desformylflustrabromine relieves the noncompetitive Aβ1-42 blockade (62). It will be an 
important (and challenging) effort to delineate the structural and conformational parameters 
that yield competitive and noncompetitive Aβ – α7 nAChR interaction.     
4. The NACHR - Aβ INTERACTION LEADS TO RECEPTOR ACTIVATION AND RECEPTOR INHIBITION  
The evidence for an inhibitory versus a stimulatory role for Aβ on α7 nAChRs is fairly 
equally divided in the literature (Table I).  Superficially, these reports appear contradictory; 
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however potential underlying issues regarding the origin of the receptor populations and 
specifics of the biological preparations as well as detection methods differ amongst laboratories 
will be discussed.  Differing effects of Aβ on α7 nAChRs indicate that the details regarding cell 
type, subcellular location, subunit stoichiometry, accessory protein population, lipid 
composition, and post-translational modifications of the receptor may significantly influence 
receptor properties; as has been shown many times previously for this receptor class (63-67).   
In these studies, an equally important, but often overlooked variable is the Aβ peptide itself.  As 
discussed above, early investigations did not characterize the conformation and aggregation 
state of the Aβ peptide stock solutions utilized.  However this is changing; some studies 
discussed below included this information and will be discussed in terms of the results 
obtained.     
4.1 α7 NACHR ANTAGONISM 
The first indication that Aβ1-42 and nAChRs functionally interact demonstrated that Aβ1-42 
inhibited nAChR currents recorded from GABAergic interneurons in acutely prepared rat 
hippocampal slices (68). Caged-carbachol-induced currents measured with whole cell 
recordings were maximally inhibited (39%) with a dose of 500 nM peptide; doses as low as 100 
nM were effective.  These effects were rapidly reversible under whole-cell recording conditions.  
One of the Aβ-sensitive channels they characterized using patch clamp recordings was sensitive 
to the α7-selective antagonist MLA.  Thus, rat hippocampal interneurons possess α7 nAChRs 
that are reversibly antagonized by Aβ1-42 via a mechanism that decreases the probability of 
opening.   
Subsequent work from this same group studied Aβ1-42 effects on nAChRs expressed in 
Xenopus oocytes (57).  Co-application of a maximal dose of carbachol and 1 µM Aβ1-42 to 
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oocytes expressing rat α7 nAChRs resulted in no effect on α7 nAChRs currents in contrast with 
their previous findings in hippocampal interneurons; further suggesting that the in situ 
environment, such as the cell system utilized for expression, can significantly alter receptor 
properties (69, 70).   
α7 nAChR antagonism was also observed in rat hippocampal neuronal cultures, it was 
demonstrated that the response of both somato-dendritic and presynaptic α7 nAChRs was 
rapidly and almost completely blocked by exposure to 100 nM Aβ1-42 and they reported an IC50 
value of 7.5 nM (56).  Full recovery occurred within 5 min of washout. This functional 
antagonism appeared noncompetitive from [125I]-BTX binding assays.  Additional experiments 
demonstrated that Aβ blockade was voltage-independent, did not result from open channel 
block, and likely resulted from interaction with the N-terminal extracellular domain of the 
receptor.  Furthermore, it was determined that intracellular Ca2+ and G-protein activity was not 
necessary for inhibition of α7 nAChR function by Aβ1-42, suggesting that prior receptor 
activation did not mediate antagonism.   
Pym et al. (58) expressed human α7 nAChRs in Xenopus oocytes and found these 
receptors to be antagonized by Aβ1-42 (and Aβ1-40).  Maximum acetylcholine currents were 
inhibited approximately 50% in the presence of 10 nM of either peptide.  Given that binding 
studies indicated that Aβ1-42 exhibits higher affinity than Aβ1-40 suggests that, at this 
concentration, the dose-response curves over lap.  Concentrations in the range of 1 pM – 100 
nM were tested and failed to activate the receptor.  Similar to the above described studies, Pym 
et al. (58) found that Aβ effects were reversible.   Grassi et al. (55) also reported that human α7 
nAChRs expressed in Xenopus laevis oocytes were antagonized by 100 nM Aβ1-42.  Antagonism 
was non-competitive and an analysis of a dose response study for inhibition of currents elicited 
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by 100 µM ACh yielded an IC50 value of 90 nM.  Attempts to activate these receptors with 10 
nM Aβ1-42 were unsuccessful.   Taken together, this set of studies suggests that soluble (human) 
Aβ does not activate human α7 nAChRs and are noncompetitively antagonized by Aβ peptides.  
Again it must be emphasized that the conformation and aggregation state of the Aβ 
preparations used in the studies above is unknown. 
A contrasting result was recently obtained when human neuroblastoma cells that 
express α7 nAChRs were exposed to human oligomeric Aβ1-42 (39).  The results from Young et 
al. (2009) were very similar to a series of studies from Dineley’s group utilizing rat hippocampal 
slices and both human and rat oligomeric Aβ1-42 (38, 50).  Concentrations in the picomolar to 
nanomolar range of oligomeric Aβ1-42 applied to SY5Y neuroblastoma cells resulted in ERK 
MAPK activation and this was blocked by the competitive antagonists MLA and BTX (39).  These 
findings again emphasize that the conformation and aggregation state of the Aβ peptide 
preparation is a critical factor in the study design. 
The results discussed above were obtained from homomeric α7 nAChRs based upon 
receptor kinetics and pharmacological properties (in situ recordings) or through heterologous 
expression in Xenopus oocytes, for example.  An α7-containing heteromeric nAChR was 
described a short time ago by Drs. Wu and Lukas in basal forebrain cholinergic neurons (71).   In 
this study, it was demonstrated that nAChRs expressed on freshly dissociated cholinergic 
medial septum/ diagonal band (MS/DB) neurons exhibit mixed kinetic and pharmacological 
properties of α7- and β2-containing nAChRs.  These ‘mixed’ properties were absent in MS/DB 
neurons prepared from β2 nAChR knock-out mice.  Functional antagonism of α7β2 nAChRs 
expressed on cholinergic MS/DB neurons was demonstrated at Aβ1-42 concentrations as low as 
1 nM; 100 pM was ineffective.  Additionally, it was demonstrated that oligomeric Aβ1-42 more 
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effectively antagonized these receptors than fibrillar Aβ1-42; monomeric Aβ1-42 had no effect.   
Such selective sensitivity to relatively low concentrations of oligomeric Aβ1-42 and the necessity 
of nAChR function in maintenance of the cholinergic phenotype suggests that the selective 
vulnerability of the basal forebrain cholinergic system during early AD may in part be due to 
blockade of this heteromeric α7β2 nAChR by oligomeric Aβ assemblies occurring due to AD 
progression.   
In all cases discussed above in which functional antagonism was reported, inhibition 
required at least 1-10 nM Aβ and block was typically incomplete, but at least 30%.  These 
studies are best summarized as rat and human α7 nAChR inhibition by Aβ1-42 peptide required 
pre-application of the peptide; receptor inhibition was reversible and exhibited noncompetitive 
binding properties (55-58, 68, 72). 
4.2 α7 NACHR ACTIVATION BY OLIGOMERIC ASSEMBLIES OF Aβ1-42 
While an interaction between α7 nAChRs and Aβ peptide is well-established, in the 
presence of Aβ, α7 nAChRs rapidly desensitize making direct electrophysiological recordings a 
challenge.  Rat α7 nAChRs expressed in Xenopus oocytes were activated following application of 
femtomolar to nanomolar concentrations of Aβ1-42 (54).  Analysis of the Aβ1-42 preparation by 
non-denaturing Tris-Tricine gel electrophoresis indicates that the Aβ used in these experiments 
was primarily hexameric oligomers with additional components of trimers and monomers (38).  
Receptor activation led to Ca2+ influx as evidenced by a reduction in current amplitude when 
Ca2+ in the recording solution was replaced by Ba2+, thus preventing the activation of the 
endogenous Ca2+-activated chloride current that enhances membrane depolarization and 
current amplitude.  Aβ1-42 activation of α7 nAChRs was blocked by the α7-selective antagonist 
MLA and cross-desensitized by the α7-selective agonist DMXB [3-(2,4-dimethyoxybenzylidene)-
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anabaseine], suggesting that the α7 nAChR ligand binding domain and the Aβ1-42 binding site at 
least partially overlap.  The lowest doses that were effective in this study (100 fM – 10 pM) and 
the observation that Aβ1-42 was more potent in activating α7 nAChRs than Aβ1-40, are consistent 
with the binding studies performed by Wang et al. (28) in which it was observed that α7 
nAChRs exhibit higher affinity for Aβ1-42 versus Aβ 1-40.  While it was demonstrated that Aβ 
peptides could directly activate α7 nAChRs; these currents were small (~200 nA).  Furthermore, 
high doses or prolonged exposure to Aβ1-42 led to receptor inhibition, possibly through a 
desensitization mechanism (54).  This was suggested by the inverted U shape of the dose – 
response curve and the observation that more than one exposure or pre-exposure to Aβ1-42 led 
to α7 nAChR inactivation.   In summary, rat α7 nAChRs expressed by Xenopus oocytes are 
responsive to physiologically relevant doses of oligomeric Aβ1-42; however, these currents are 
relatively small indicating that oligomeric Aβ1-42 appears to be highly desensitizing leading to 
receptor inactivation. 
One strategy to overcome the desensitizing nature of Aβ1-42 for α7 nAChRs and gain 
signal-to-noise in measurements of receptor activation is to exploit the high Ca2+permeability of 
these receptors.  As such, α7 nAChR activation commonly leads to Ca2+-induced Ca2+ release 
(CICR); voltage-gated Ca2+ channels are another component of the overall intracellular Ca2+ 
signal in cases where nAChRs evoke significant changes in membrane potential.  The Nichols’ 
laboratory took advantage of this circumstance by utilizing confocal imaging in combination 
with fluorescent Ca2+-indicator dyes to record increases in intracellular Ca2+ in isolated 
presynaptic nerve endings purified from rat hippocampus and neocortex (52).  These efforts 
determined that picomolar Aβ1-42 directly led to sustained increases in presynaptic Ca
2+ via 
nAChRs.  The effect of Aβ1-42 was sensitive to BTX, mecamylamine (MEC), and dihydro-β-
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erythroidine (DHβE), indicating the involvement of both α7-containing and non-α7-containing 
nAChRs.  Interestingly, it was discovered that α7-containing nAChRs are largely involved in the 
presynaptic actions of Aβ at picomolar concentrations whereas higher nanomolar 
concentration of Aβ involves mainly non-α7-containing nAChRs.  Prior exposure of these 
preparations to Aβ occluded subsequent nicotine-evoked increases in presynaptic Ca2+.  This 
and the fact that nicotine, albeit at relatively high concentration, could overcome the occlusion 
effect of Aβ1-42 suggested that the Aβ and the α7 nAChR ligand binding site significantly overlap.  
Subsequent studies utilizing presynaptic terminals isolated from the hippocampus and cortex of 
nicotinic receptor knockout mice for either the α7 or β2 nAChR subunit, determined that Aβ-
mediated increases in intracellular Ca2+ were mainly mediated by β2-containing nAChRs in the 
hippocampus and α7 nAChRs in the cortex (53, 73).   Perhaps the species difference between 
the two studies underlies the failure to detect α7 nAChR presynaptic involvement in the 
hippocampus of mice.  However, yet another study from this group utilized a neuroblastoma 
cell line (NG 108-15) transfected with mouse α7 nAChR cDNA found that picomolar – 
nanomolar soluble Aβ1-42 induced increased intracellular Ca
2+ within axonal varicosities that was 
blocked by the α7 nAChR antagonist, BTX (73).  Interestingly, cholesterol depletion with methyl-
β-cyclodextrin significantly attenuated these responses, suggesting that Aβ-sensitive α7 nAChRs 
reside within lipid rafts at presynaptic sites.  These findings further reinforce that the lipid 
composition surrounding nAChR receptor transmembrane domains is an important variable 
contributing to nAChR functional profiles (74, 75).   
All in all, these studies demonstrate that low concentrations (femtomolar-picomolar) of 
oligomeric (e.g., trimer, hexamer) Aβ1-42 can activate α7 nAChRs in situ and heterologously 
expressed in Xenopus oocytes.  Receptor activation increases intracellular Ca2+ and can 
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potentiate neurotransmitter release.  However, higher Aβ1-42 concentrations lead to receptor 
inactivation, likely through a desensitization mechanism.  These results put forth the possibility 
that, under normal physiologic conditions, Aβ and α7 nAChR interaction could lead to receptor 
activation in vivo, as has been recently demonstrated by Puzzo et al. to be discussed in the next 
section (36, 37). 
5. FUNCTIONAL CONSEQUENCES OF THE α7 NACHR – Aβ INTERACTION   
Activation of nAChRs causes membrane depolarization and, directly or indirectly, 
increases the intracellular Ca2+ concentration.  Thus, when nAChRs are expressed on 
presynaptic membranes their activation generally increases the probability of neurotransmitter 
release.  When expressed on postsynaptic membranes, nAChR-initiated increases in 
intracellular Ca2+ and depolarization activate intracellular signaling mechanisms that contribute 
to neuron homeostasis, synaptic plasticity, learning and memory (for review, see (76).  As is the 
case for receptor activation by ACh or nicotine, Aβ activation of α7 nAChRs runs the gamut of 
these responses. 
5.1 SIGNAL TRANSDUCTION CONSEQUENCES OF THE α7 NACHR – Aβ INTERACTION   
Since the discovery of an α7 nAChR – Aβ interaction several groups have mapped out 
some of the downstream consequences of this association: Ca2+ influx, ERK MAPK activation via 
the PI3K pathway that results in CREB phosphorylation in both a PKA- and Rsk2-dependent 
manner (38, 39, 50, 52, 54, 77).   The studies by Dineley et al. (50) and Bell et al. (38) were 
performed on organotypic hippocampal slice cultures; specificity of the effects occurring via α7 
nAChRs was demonstrated with the α7-selective antagonists MLA and BTX.  ERK activation 
occurred rapidly and at concentrations as low as 10 pM.   
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Extended exposure to high (nanomolar) concentration of Aβ1-42 led to down-regulation 
of ERK MAPK activity; this is also observed in hippocampal samples from aged Tg2576 in which 
Aβ is produced in excess from young adulthood onward (38, 50).  Interestingly, extended 
exposure to nanomolar Aβ 1-42 up-regulates α7 nAChRs in hippocampal cultures, comparable to 
the effects of chronic exposure to nicotine (50).  Likewise, in the Tg2576 hippocampus α7 
nAChRs continue to up-regulate with age as Aβ accumulates, providing further evidence that Aβ 
and α7 nAChRs interact in vitro and in vivo (50, 78).  Dysregulation of α7 nAChRs, ERK MAPK, 
and the downstream transcription factor CREB in the hippocampus of Tg2576 mice occurs 
concomitant with the onset of hippocampus-dependent learning and memory impairments 
(50).  These combined in vitro findings and in vivo observations suggest that, in hippocampus, 
physiological concentrations of Aβ1-42 impinge upon signal transduction cascades important for 
cell homeostasis, synaptic plasticity, learning and memory.  Short exposure times (minutes) and 
moderate concentrations (picomolar – low nanomolar) do not lead to permanent changes in α7 
or the ERK MAPK cascade; higher doses and extended exposure time lead to dysregulation of 
α7, ERK MAPK, and CREB accompanied by learning and memory impairments.    
Young et al. obtained very similar results to those from Dineley’s group utilizing human 
SY5Y neuroblastoma cells exposed to human oligomeric Aβ1-42.  Oligomeric Aβ application 
resulted in ERK MAPK activation and this was blocked by the α7 nAChR competitive antagonist, 
MLA, and U0126 compound that inhibits the ERK MAPK upstream kinase, MEK (39). 
Utilizing primary neuronal cultures prepared from mouse cortex and hippocampus 
Abbot et al. demonstrated that acute exposure to nanomolar (400) Aβ1-42 leads to Akt 
phosphorylation via α7 nAChRs (77).  Akt is closely associated with PI3K activation which itself is 
involved in signal transduction pathways necessary for neuroprotection as well as synaptic 
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plasticity, learning and memory (79).  nAChRs have long been implicated as playing a role in 
each of these processes; in neuron models for α7 nAChR-mediated neuroprotection, activation 
of the PI3K-Akt pathway is a crucial downstream effector of nicotine-induce anti-apoptotic 
signaling (80, 81) (82).  We previously discussed the work of Dineley et al. and Bell et al., in 
which acute exposure of organotypic hippocampal slice cultures to picomolar-nanomolar Aβ1-42 
(and nicotine) led to ERK MAPK activation via α7 nAChRs (50).  Bell et al. (38) further showed 
that Aβ1-42 (and nicotine) couples to ERK via PI3K in an α7 nAChR-dependent manner.  Abbott et 
al., however, did not test whether PI3K activity was necessary for the Akt phosphorylation 
observed following acute Aβ1-42 exposure; thus there may exist subtle molecular differences 
between the two systems (77).   
To summarize, α7 nAChRs acutely exposed to Aβ1-42 leads to activation of signal 
transduction cascades associated with neuroprotection, synaptic plasticity, learning and 
memory in an α7 nAChR-dependent manner (Figure 1).  The concentration range that was 
effective (picomolar-nanomolar) suggests that endogenous Aβ may serve a modulatory role in 
synaptic transmission, plasticity, and even neuroprotection (36, 46, 47, 83-85).  Further 
discussion on this topic will be covered in the next section. 
The fact that α7 nAChRs also reside on glial cells, notably astrocytes, immediately 
implies a major physiological role in astrocytic function, since α7 nAChRs flux Ca2+, and changes 
in intracellular Ca2+ are the basis of astrocytic “excitability” (86, 87); (88). These observations 
clearly imply that the relationship between nAChRs and Aβ is a dynamic one and relies on 
several factors such as the in situ environment in which the nAChR is expressed (somatic, 
dendritic, presynaptic; neuronal, astrocytic, microglial) as well as the in situ status of Aβ 
(concentration, aggregation state, regional distribution).   
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5.2  NEUROTRANSMISSION, SYNAPTIC PLASTICITY, LEARNING AND MEMORY 
The Nichols’ laboratory has performed several studies investigating the ability of soluble 
Aβ1-42 to influence neurotransmitter release through activation of presynaptic nAChRs (51, 52, 
73).  Initial studies demonstrated that soluble Aβ1-42 activates nAChRs on presynaptic terminals 
isolated from rat neocortex and hippocampus (52).  The observations that Aβ-induced nAChR 
activation led to elevation of presynaptic Ca2+ and that prior activation of presynaptic nAChRs 
attenuated subsequent responses to Aβ1-42 suggested that this interaction could lead to altered 
synaptic transmission; however this study by Dougherty et al. did not directly test that 
outcome.   
 To address whether presynaptic α7 nAChR – Aβ interaction impinges upon 
neurotransmission, the same group then utilized the well-established paradigm for nAChR-
mediated dopamine (DA) release from prefrontal cortex to test the hypothesis that Aβ-
activation of presynaptic nAChRs could lead to neurotransmitter release in vivo (51); (89).  It 
has been shown previously that both α7-containing and α4β2 nAChR subtypes are involved in 
prefrontal cortex DA release; in this study, soluble Aβ was perfused into mouse prefrontal 
cortex and the effect  on the release of DA outflow via micorodialysis was assessed (90, 91).     
In the presence of tetrodotoxin, Aβ1-42 at 100 nM evoked the release of DA to ~170% of 
baseline.  Aβ1-42-evoked DA release was sensitive to antagonists of α7 nAChRs and was absent 
in mice in which the α7 nAChR subunit had been genetically deleted, but was intact in mice 
harboring a null mutation for the β2 nAChR subunit (92, 93).  Very low relative concentrations 
(picomolar) of Aβ1-42 caused a slowly developing and long-lasting depression of DA outflow in 
the prefrontal cortex.  Given that the Aβ1-42 in these studies was delivered through reverse 
dialysis, the time to achieve maximal dose is unknown, but likely on the minutes’ time scale; 
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therefore, picomolar Aβ1-42 may evoke a low sustained level of presynaptic Ca
2+ rise, leading to 
synaptic depression.  It will be of interest if fast delivery of such a concentration of Aβ1-42 has 
the same effect.  Nonetheless, the cumulative work of Dougherty et al. (52) and Wu et al. (51) 
provide compelling evidence that Aβ1-42, most likely acting through α7 nAChRs, alters 
neurotransmitter release and transmission at certain cortical synapses. 
In addition to directly modulating neurotransmitter release, Aβ1-42 has additional 
synaptic effects by modulating NMDA receptor function through a trafficking mechanism.  In 
this study, cortical neuron cultures were used as a cellular model to study glutamatergic 
synapses and it was found that exposure to high (µM) concentrations of Aβ1-42 for prolonged 
periods of time (>30 minutes), led to NMDA receptor endocytosis in an α7 nAChR- and Ca2+-
dependent manner (31).  The mechanism involved Ca2+-dependent activation of protein 
phosphatase 2B that led to striatal-enriched phosphatase (STEP) dephosphorylation and 
activation, which in turn resulted in dephosphorylation of the NR2B NMDA receptor subunit on 
a tyrosine residue (Tyr1472, a STEP target).   NR2B Tyr1472 dephosphorylation correlated with 
receptor endocytosis and depression of NMDA-evoked currents in cortical neuron cultures.   
 Modeling synaptic deficits of early AD by infusing 300 pmoles of Aβ1-40 per day for 11-14 
days into rat hippocampus followed by in vivo HFS-induced LTP at Schaffer collateral – CA1 
synapses Chen et al. found that α7 nAChRs were involved in Aβ1-40–induced depression of 
synaptic transmission and deficits in LTP (35, 94).  Utilizing the α7 nAChR partial agonist, DMXB, 
it was demonstrated that DMXB induced EPSPs were impaired in Aβ1-40 infused rat 
hippocampus (95).  In addition,   Aβ1-40 infused rats also demonstrated impaired LTP that was 
rescued with DMXB.  Control experiments demonstrated that: 1) DMXB enhanced in vivo 
recorded EPSPs in untreated rats; 2) DMXB enhanced EPSPs were blocked by BTX but not DHβE, 
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an α4β2 nAChR antagonist; 3) blocking α7 nAChRs with BTX and MLA (but not α4β2 nAChRs 
with DHβE) blocked in vivo LTP; 4) BTX blocked DMXB enhancement of LTP.   Finally, evaluation 
of input/output curves as well as post-tetanic potentiation and paired-pulse facilitation 
suggested that Aβ1-40 infusion leads to diminished presynaptic Ca
2+ influx that led the authors to 
propose a model in which reduced EPSP in Aβ1-40 infused rats arises from a decline in 
presynaptic glutamate release due to α7 nAChR dysfunction.   Collectively, the studies by Chen 
et al. suggest that Aβ-induced blockade of α7 nAChRs can negatively affect synaptic plasticity 
and, by extrapolation, possibly learning and memory processes (35, 94).  
 Gu and Yakel published additional exciting in vivo evidence that Aβ at high (nanomolar) 
concentration interacts with presynaptic septal cholinergic α7 nAChRs to affect Schaeffer 
collateral (SC) to CA1 plasticity (40).  Septal cholinergic stimulation was achieved either by 
electrical stimulation or via an optogenetic approach.  The type of plasticity depended upon the 
timing of septal cholinergic stimulation relative to the SC input; cholinergic input activated 100 
or 10 msec prior to SC stimulation resulted in α7 nAChR-dependent long-term potentiation 
(LTP) or short-term depression, respectively. Plasticity was blocked by the α7 nAChR antagonist 
MLA and absent in α7 nAChR knockout mice; the α4 nAChR-selective antagonist DHβE had no 
effect. Moreover, these two forms of α7 nAChR-dependent plasticity were disrupted by either 
10 or 100 nM (but not 1 nM) Aβ exposure suggesting again that inactivation of α7 nAChRs has 
negative effects on synaptic plasticity. 
In a series of studies utilizing low (picomolar) concentration of oligomeric Aβ, Puzzo et 
al. have developed the idea that endogenous Aβ serves as a positive modulator of hippocampal 
synaptic transmission via interaction with (presumably) presynaptic α7 nAChRs (36, 37).  At the 
outset, they demonstrated that 200 pM Aβ1-42 enhanced Schaffer collateral – CA1 LTP using 
Page 22 of 54
Ac
ce
pte
d M
an
us
cri
pt
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
α7 NACHR & AD 
 22 
theta-burst stimulation; enhanced LTP was not achieved if tetanus was not applied nor when a 
scrambled peptide was perfused with tetanus, and was absent in hippocampal slices prepared 
from α7 nAChR null-mutant mice.  Investigations into the mechanism of the Aβ-induced 
enhancement of LTP ruled out that Aβ does not affect spontaneous neurotransmitter release; 
nor did it affect NMDA or AMPA receptor currents.  The authors concluded that 200 pM Aβ1-42 
increases neurotransmitter release in an α7 nAChR-dependent manner during the tetanus.  
These results are consistent with a presynaptic effect of Aβ on α7nAChRs. However, since 
astrocytic Ca2+ elevations lead to gliotransmitter release, which can then contribute to synaptic 
strengthening in the dentate gyrus (96), it is possible glial α7 nAChRs contribute to synaptic 
modulation and plasticity.  This potential scenario will be discussed in the next section. 
 In the same set of studies, Puzzo et al. (36) report that 200 pM Aβ1-42 delivered through 
bilateral cannulae to the dorsal hippocampus also enhances baseline learning and memory in 
wildtype mice.  Injections were performed prior to training in the Morris water maze and for 
contextual fear conditioning.  Both paradigms are hippocampus-dependent learning and 
memory paradigms; Morris water maze tests spatial navigation learning and memory while 
contextual fear conditioning tests associative learning and memory.  In both tasks, mice 
receiving 200 pM Aβ1-42 showed improved performance during the testing phase; neither 
wildtype receiving scrambled peptide nor α7 nAChR null mice receiving Aβ1-42 showed signs of 
cognitive enhancement.  Collectively, these findings suggest that Aβ1-42 may be an endogenous 
neuromodulatory peptide that, at least in hippocampus, utilizes α7 nAChRs to exert its effects.   
 A second publication from Puzzo et al. tackled this ambitious hypothesis (37).  First, it 
was demonstrated that hippocampal (but not cerebellum) Aβx-42 level increased following 
theta-burst stimulation of Schaffer collaterals and training for contextual fear memory.  The 
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next experiment reduced endogenous rodent Aβ through antibody depletion and siRNA 
methodologies prior to hippocampal LTP induction or training for contextual fear memory.  The 
resultant inhibition of LTP and contextual learning lends further support to the model 
developed from the set of studies described above.  Specifically, antirodent Aβ antibodies and 
siRNA against rodent APP inhibited Schaffer collateral – CA1 LTP as well as contextual fear 
memory; exogenous application of human Aβ1-42 oligomers (but not monomers) restored 
proper function.  Furthermore, Aβ depletion strategies that diminished both post-tetanic 
potentiation (due to enhanced neurotransmitter release) and LTP in wild type hippocampal 
slices were unsuccessful in slices obtained from α7 nAChR knockout mice.  Thus, it appears that 
endogenously produced oligomeric Aβ is capable of supporting hippocampal synaptic plasticity, 
learning and memory and utilizes α7 nAChRs.   
 From these sets of studies, Aβ interaction with α7 nAChRs clearly has both positive and 
negative effects on neurotransmitter release, synaptic transmission, synaptic plasticity, learning 
and memory.  What decides one outcome over the other?  The simplest answer to this question 
is Aβ concentration in that picomolar concentrations of focally (acutely) delivered Aβ 
potentiates glutamatergic neurotransmission, synaptic potentiation, and enhanced learning and 
memory.  High concentrations (nanomolar-µM) of acutely applied Aβ led to reduced synaptic 
NMDA receptors, reduced glutamatergic transmission and, presumably, impaired synaptic 
potentiation.  Alternatively, Aβ-induced LTP impairment and cognitive deficits can be achieved 
with moderate concentrations of Aβ when it is delivered for an extended time period (300 
pmoles/day).   Thus, as is the case with traditional nAChR agonists, acute exposure to moderate 
doses leads to receptor activation; exposure to high concentrations or prolonged exposure to 
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moderate concentrations can lead to receptor inactivation through a desensitization 
mechanism.   
5.3  GLIAL α7 NACHRS 
An emerging issue in the field of α7 nicotinic receptor research is to decipher the 
functional role of these receptors on glial cells. Glial cells outnumber neurons in the brain and 
their traditional designation as housekeeping cells continues to be reconsidered as 
experimental observations indicate direct glial contributions synaptic function.  Glial cells 
express functional receptors to many neurotransmitters and neuromodulators including, 
glutamate, GABA, ATP and ACh and there is now evidence of α7 nAChRs expression on most of 
the major glial types: microglia, NG2 cells and astrocytes (97-100).  The activation of α7 nAChR 
on cultured microglia reduces the release of a major inflammatory mediator in the CNS, TNF-α 
(87). Given that TNF-α is abundantly found in the AD brain suggests that, under AD-like excess 
Aβ conditions, these receptors may be chronically inactivated through prolonged interaction 
with Aβ.  Brain microglia and therefore brain inflammation are subject to α7 nAChR regulation 
which has direct relevance to AD.  
Because astrocytes can release neurotransmitters to modulate neuronal excitability and 
synaptic transmission, there is much interest in the role of astrocytes in brain function. Since α7 
nAChRs flux Ca2+, and changes in intracellular Ca2+ are the basis of astrocytic “excitability”, the 
activation of these receptors could be a potent mechanism for modulating astrocytic activity 
(88). In cultured hippocampal astrocytes Sharma and Vijayaraghavan (86) found that focal ACh 
application induced inward currents in recorded astrocytes which were blocked by MLA. Ca2+ 
imaging experiments revealed intracellular Ca2+ elevations that persisted for tens of seconds, 
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which were shown to be caused by an extracellular Ca2+ influx eliciting ryanodine receptor 
mediated CICR.  
Evidence of α7 nAChR-mediated astrocyte functional responses in slice preparations is 
scarce.  However, we have shown astrocytic Ca2+ elevations in slice preparations of 
hippocampus and neocortex elicited by focal nicotine and Aβ1-42 (100 pM) application; these 
experiments were performed in the presence of tetrodotoxin (TTX) suggesting that local 
network activity was not responsible for the observed  astrocytic Ca2+ elevations (Parri and 
Dineley, 2008a). The α7 nAChRs competitive antagonist, MLA, blocked these responses.   
Additional evidence for functional α7 nAChRs on glial cells comes from α7 nAChR 
mediated inward currents in area CA1 NG2 cells from hippocampal slices in response to 
nicotine and (101).  These currents were potentiated by the potent α7 nAChR allosteric 
modulator PNU-120596 and blocked by the α7 nAChR selective antagonist MLA, but not DHβE, 
an α4 nAChR specific antagonist. These studies have significance because NG2 cells have been 
postulated to be glial precursors; therefore, Aβ – α7 nAChR interaction may differentially lead 
microglial versus astrocyte genesis.   
In summary, evidence is emerging that glial-resident α7 nAChRs can functionally 
contribute to NG2 cell development, modulate TNF-α production by microglia, and induce 
intracellular Ca2+ signaling in astrocytes that impinge upon neuronal synaptic signaling.  In some 
cases, it is evident that Aβ modulates these responses therefore implicating the Aβ – α7 nAChR 
interaction on glia in AD inflammation and possibly cognitive function.    
6. NACHRS, Aβ, AND ALZHEIMER’S DISEASE 
Understanding the molecular mechanism behind the selective vulnerability of 
cholinergic neurons to Aβ toxicity would greatly advance our capabilities in treating AD.  The 
Page 26 of 54
Ac
ce
pte
d M
an
us
cri
pt
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
α7 NACHR & AD 
 26 
fact that vulnerable neuron populations happen to be enriched for α7 nAChRs may provide an 
important clue.  As discussed previously, one possibility as Aβ accumulates during AD is that the 
neuroprotective function of nAChR activation is blocked by the antagonizing effect of Aβ 
peptides.  Another possibility is that the Aβ – nAChR interaction under disease conditions 
directly contributes to neurotoxicity.  Potential mechanisms for each of these possibilities will 
be discussed in the following sections. 
6.1. NACHRS PROTECT AGAINST Aβ TOXICITY 
In vitro studies utilizing cultured neurons have demonstrated that α7 nAChRs mediate, 
at least in part,  the neuroprotective effects of nicotine against Aβ toxicity (102).  Protection 
against Aβ toxicity is proportional to the number of α7 nAChRs expressed by cultured cells 
(103).  Chronic exposure to Aβ 1-42 in vitro leads to up-regulation of α7 nAChRs in a manner 
similar to the effects of chronic nicotine treatment (50, 78).  Tg2576 mice that produce 
excessive Aβ continue to up-regulate cortical and hippocampal α7 nAChRs as these animals age 
possibly providing an explanation as to why this AD model does not exhibit a cholinergic lesion 
phenotype nor significant loss of hippocampal and neocortical neurons (50, 78, 104, 105) (106, 
107).     
α7 nAChR-mediated neuroprotection against Aβ is via activation of the PI3K pathway; 
several lines of evidence suggest that this can occur through transactivation of src and tyrosine 
kinase receptors, including the high-affinity NGF receptor, TrkA (80, 108-111).  Paradoxically, at 
low to moderate concentrations of soluble Aβ1-42, PI3K is also activated, suggesting that when 
Aβ is soluble and at non-disease concentration, the Aβ - nAChR interaction can lead to 
activation of neurotrophic mechanisms (38).  In vitro and in vivo, chronic nicotine leads to an 
increase in TrkA, in addition to α7 and α4β2 nAChRs; in vivo, this is accompanied by up-
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regulation of ChAT and VAChT in hippocampus (111-113).  Increased TrkA is neuroprotective 
against Aβ toxicity; high concentrations of Aβ are neurotoxic and block nicotine-induced TrkA 
upregulation (110, 111).  Thus, nAChRs are neuroprotective both by modulating the 
neurotrophic system crucial for the maintenance of cholinergic neuron integrity as well as 
stimulating signal transduction pathways that support neuron survival.  Additionally, these 
studies suggest that in a situation of excess Aβ, nAChR function is blocked thus blocking its 
trophic activity and possibly contributing to Aβ toxicity.   Taken together, one might imagine 
that under normal physiologic conditions, an Aβ – nAChR interaction provides a trophic signal; 
as Aβ accumulates, this interaction either blocks nAChR-mediated trophism or the Aβ – nAChR 
interaction under these circumstances becomes toxic.   
6.2. MULTIPLE OPPORTUNITIES FOR AN α7 NACHR – Aβ INTERACTION TO CONTRIBUTE TO AD ETIOLOGY 
Estimates of Aβ content in non-demented brain report picomolar values, however these 
estimates increase to nanomolar quantities for AD brain (46, 47, 83).  Several studies report 
that prolonged exposure of nAChRs to nanomolar Aβ results in significant block of receptor 
function (54-58, 68).   This suggests that under disease conditions an Aβ – nAChR interaction 
would interfere with the normal function of these receptors.  Given the overwhelming evidence 
that nAChRs perform a neuroprotective role, an Aβ – nAChR interaction under elevated Aβ 
conditions may exacerbate the toxicity of Aβ by diminishing the neuroprotective signaling 
performed by these receptors.  The current literature indicates that additional outcomes of an 
Aβ – nAChR interaction under ‘high Aβ’ conditions could yield 1) perturbation and dysregulation 
of signal transduction mechanisms involved in synaptic plasticity and homeostasis; 2) receptor – 
peptide complex internalization; 3) cell toxicity; and 4) plaque seeding.  The evidence for these 
mechanisms will be discussed in the following section. 
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While there is a general consensus that the presence of excess Aβ is perhaps the most 
fundamental neurotoxic event in AD, several lines of evidence indicate that oligomeric, soluble 
forms of Aβ, rather than amyloid plaques, initiate the cognitive deficits characteristic of the 
disease (114) (115).  For example, transgenic mouse models for AD in which Aβ is over 
produced and accumulates in the CNS develop memory impairments long before plaques are 
detected and in the absence of significant neuronal loss (78, 104, 105, 116).  Furthermore, 
introduction of Aβ oligomers produced in vitro or in vivo induces learning and memory deficits 
in wildtype rodents that resemble those of transgenic models for AD (33, 34, 117).  Therefore, 
some of the cognitive impairments in AD may not be associated with extensive neuronal death; 
rather, they may be the result of more subtle functional changes induced by soluble Aβ.  It will 
be important for future studies of the Aβ – nAChR interaction to attribute outcomes of this 
interaction not only to the concentration of soluble Aβ but also to specific structures and 
aggregates of the peptide. 
In addition to extracellular deposits of insoluble Aβ in plaques that are a primary 
histopathological diagnostic marker for AD, observations made as the 20th century yielded to 
the 21st, identified Aβ immunostaining within neurons and glia of post mortem AD samples 
(118, 119).  Later, it was discovered that α7 nAChRs are not only expressed on neurons, this 
receptor is expressed by astrocytes and microglia (86, 87).  Consequently, several groups have 
investigated the possibility that an α7 nAChR – Aβ interaction on these cell types are part of AD 
etiology.   
In a series of publications from Wang, Nagale, D’Andrea and colleagues, this group first 
explored the model that an α7 nAChR – Aβ interaction leads to intracellular accumulation of Aβ.  
Initial work utilizing post mortem AD brains and immunostaining approaches revealed that Aβ1-
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42 was localized intracellularly in neurons and astrocytes of AD brains; neurons and astrocytes 
that had accumulated large amounts of Aβ 1-42 also highly expressed α7 nAChRs (41, 120-123).  
In neuroblastoma cells transfected with α7 nAChR cDNA, transfected cells exhibited rapid 
binding, internalization and accumulation of exogenous Aβ1-42, but not Aβ1-40; this 
internalization was related to the level of α7 nAChR expression (41).  Further, the α7 nAChR 
antagonist, BTX, prevented Aβ1-42 uptake.  These results suggest that α7 nAChRs facilitate Aβ1-42 
internalization and may confer selective vulnerability of specific cell types to the toxic effects of 
intracellular Aβ1-42.  Nagale and colleagues took this notion a step further by suggesting that α7 
nAChR – Aβ interaction and internalization may actually lead to plaque formation when the 
host cell eventually dies and deposits the intracellular contents in the brain parenchyma (121, 
122, 124).   
The identification of α7 nAChR and Aβ within astrocytes also provided the first 
indication that nAChR – Aβ interaction may be an important event in the inflammatory 
progression of the disease (121).  These studies showed that Aβ1-42 and α7 nAChR proteins were 
co-localized in intensely GFAP-positive (activated) astrocytes in immunostained AD brain.  Since 
these studies also identified ChAT, the authors proposed a model in which Aβ and α7 proteins 
are phagocytosed by activated astrocytes in the vicinity of neuronal remnants.  As neuronal 
debris accumulates in the astrocyte, astrocyte viability is compromised and eventually kills the 
cell leaving behind Aβ deposits rich in astrocytic GFAP, and neuronal markers such as ChAT and 
α7 protein.    
A slightly different interpretation was made by Teaktong et al. (125) when they found 
that the majority of astrocytes in AD hippocampus and cortex also express α7 nAChRs; this 
group deduced that α7 nAChRs are up-regulated on astrocytes in AD.  Follow-up studies 
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determined that the number of astrocytes double-labeled with α7 nAChR and GFAP antibodies 
was increased in most areas of the hippocampus and entorhinal cortex in AD compared with 
controls suggesting that increased astrocyte alpha7 nAChRs in AD may be associated with 
inflammatory mechanisms related to degenerative processes (126).  
Although the work by Teaktong et al. and Nagale et al. utilized antibodies to α7 nAChRs 
that have since come into question as to their specificity, subsequent work from Dr. Agneta 
Nordberg’s group using 125I-BTX to quantify α7 nAChR protein supports these initial 
observations both in post mortem AD brain and primary cell culture (127-129). Subsequent in 
vitro work by Xiu et al. (129) lends support to the idea that Aβ-induced α7 nAChR up-regulation 
on astrocytes occurs in the disease: exposure of cultured primary astrocytes to picomolar – 
nanomolar Aβ1-42 for 48 hours followed by quantification of mRNA and protein with RT-PCR and 
immunoblot, respectively, resulted in up-regulation of both α7 nAChR mRNA and protein.   
A recent study utilizing cultured rat microglia found that activation of microglial α7 
nAChR leads to increased Aβ phagocytosis (130). The study found that human Aβ1-42 clearance 
was increased by nicotine as well as the cholinesterase inhibitor and α7 nAChR allosteric 
modulator galantamine; Aβ clearance was blocked by the broad nAChR antagonist MEC and the 
α7 nAChR selective antagonist MLA, but not atropine a mAChR antagonist.  Furthermore, 
galantamine-treated AD mice exhibited reduced amyloid load as did rats that received intra-
hippocampal injections of human Aβ1-42.  Thus, these studies suggest that microglia-resident α7 
nAChRs may be part of the mechanism mediating the therapeutic efficacy of this compound 
through Aβ clearance.  
The interaction of α7 nAChRs on astrocytes with Aβ peptide may provide a possible link 
between α7 nAChRs and the inflammatory processes of AD.  Analogous to its role in the 
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periphery, α7 nAChR activation on glia shunts TNF-α production and release; therefore, an 
important question to answer is under what conditions might an α7 nAChR – Aβ interaction 
lead to decreased TNF-α production as opposed to general microglial and astrocyte activation.  
It will be important to decipher this apparently complex relationship between neuroprotection, 
astrocyte activation, inflammation, and neurotoxicity, in addition to how this interaction 
contributes to the development of neuronal- and astrocyte-derived plaques in AD brain.  
Clearly, an interaction between glial-resident α7 nAChRs and Aβ may be involved in a broad 
array of outcomes during the progression of AD.  
We recently tested the hypothesis that α7 nAChRs are neuroprotective during early 
stage AD by investigating the effects of α7 nAChR gene deletion on cognitive function and 
septo-hippocampal integrity in the Tg2576 APP transgenic animal model for AD (131).  Whereas 
α7 nAChR knock-out (A7KO) mice neither show cognitive deficits nor exhibit morphological CNS 
abnormalities, we found that cognitive deficits seen in 5-months-old APP transgenic mice are 
more severe when α7 nAChR receptors are absent (A7KO-APP) (93, 131, 132).  Biochemical 
analyses on 5-months-old A7KO-APP revealed significant reduction in hippocampal and basal 
forebrain ChAT activity and loss of hippocampal neurons and markers compared to APP mice.  
Consistent with lesion studies and observations in AD brain, compromise of basal forebrain 
cholinergic function leads to similar concessions within the hippocampus of 5-months-old 
A7KO-APP mice.  These studies demonstrated that α7 nAChRs mediate neuroprotective 
mechanisms that maintain the basal forebrain cholinergic phenotype and preserve 
hippocampal integrity; loss of basal forebrain cholinergic integrity is accelerated and 
exacerbated when α7 nAChRs are absent and misfolded Aβ is in excess.   
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Data continues to accumulate demonstrating that Aβ peptides interact with α7 nAChRs 
with especially high affinity and for extended periods of time; consistent with such an 
interaction, up-regulation of α7 nAChRs mRNA and protein has been reported in astrocytes, 
peripheral blood leukocytes and cortical and hippocampal neurons harvested from the tissue of 
AD patients (10, 125, 133).  The additional observation that, in early AD, Aβ preferentially 
accumulates in neuronal populations that are enriched for α7 nAChRs may be one reason for 
the selective vulnerability of the basal forebrain cholinergic system to Aβ toxicity.   
In one study, mRNA expression levels of nicotinic and muscarinic AChR subtypes and 
ChAT were measured in single cells isolated from the cholinergic basal forebrain of post-
mortem AD tissue (and non-cognitively impaired controls) then individually analyzed using 
microarray methods. No differences in mRNA expression were observed for the other nAChR 
subunits, mAChR subtypes or ChAT (16). However, cells from AD basal forebrain exhibited a 
significant up-regulation of α7 nAChR subunit mRNAs (16).  This increase in α7 nAChR 
expression levels within CBF neurons was inversely correlated with Global Cognitive Score and 
with Mini-Mental State Examination performance (16).  We would posit that these increases in 
α7 nAChR protein within the basal forebrain result from direct interaction with Aβ and receptor 
desensitization followed by receptor up-regulation (66).  In fact, α7 nAChR-selective agonists 
are unable to activate these receptors in APP transgenic mice and recent work on human AD 
postmortem brain samples indicate that much of the receptor protein is functionally 
inactivated due to association with Aβ peptide (9, 10, 134, 135).   In addition, recent studies 
have shown that these Aβ - α7 nAChR protein complexes occur primarily in brain regions 
targeted by the cholinergic basal forebrain; disruption of this association in post-mortem AD 
cortex leads to increased availability of functional α7 nAChRs (10).  These observations suggest 
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that in AD, α7 nAChRs are likely inactive due to desensitization as a consequence of prolonged 
association with Aβ peptide.   
Based on current understanding, we propose that soluble Aβ oligomers that may lead to 
the transient activation of α7 nAChRs and subsequent initiation of both neuroprotective and 
neurotrophic signaling mechanisms that have been elucidated in vitro (38, 50, 80).  An 
additional benefit may be provided via sequestering Aβ oligomers and preventing further 
oligomerization, thus deviating Aβ from additional toxic interactions (e.g., mediators of 
glutamatergic neurotransmission; (136, 137). As AD progresses, we envision that Aβ 
accumulates and irreversibly associates in a manner that overwhelms the availability of α7 
nAChRs leading to functional blockade and loss of neuroprotective signaling.   
6.3. THERAPEUTIC OPPORTUNITIES   
While much progress has been made regarding the nature of α7 nAChR – Aβ interaction 
in vivo and in vitro, many questions remain as to the exact features of α7 nAChR – Aβ 
interaction during the initiation and progression of AD to confidently suggest viable therapeutic 
strategies.    Nonetheless, one might consider a few possibilities based on the extant literature 
reviewed here.  Several α7 nAChR agonists and positive allosteric modulators (PAMs) have been 
developed as therapeutic agents targeting central and peripheral disorders that involve pain, 
inflammation, schizophrenia, and AD (138-140).  One such compound, S-24795, was recently 
directly tested for efficacy in AD; application to homogenates prepared from  post mortem AD 
brain was found to facilitate Aβ dissociation from the receptor in order to resurrect α7 nAChR 
function and its neuroprotective properties (10, 42).  Possibly, S-24795, and other such α7 
nAChR PAMs would prove beneficial during early AD by both inhibiting and partially reversing 
Aβ binding to α7 nAChRs.  However it remains to be seen if the dislodged Aβ is then free to 
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interact in alternative yet deleterious ways.  Possibly coincident Aβ immunotherapy would 
alleviate this potential negative side effect of α7 nAChR PAM therapy.  Another possible 
strategy, albeit somewhat difficult to envision at the receptor level, would be to develop a 
compound that is capable of maintaining α7 nAChR neuroprotective signaling capabilities on 
the one hand and continue to sequester Aβ on the other.  Again, this in conjunction with 
interventions that decrease oligomeric Aβ levels might prove most efficacious. 
Assuming that, under normal physiological conditions, Aβ and α7 nAChRs interact and 
result in receptor activation implies that this interaction may serve a neuroprotective role given 
that α7 nAChRs couple to neuroprotective signaling cascades (PI3K etc).  Therefore, it seems 
imprudent to prophylatically block all
From the nAChR side of the equation, the development of a decoy nAChR-like binding 
site (presuming it is known) could prevent toxic α7 nAChR – Aβ interactions.  Direct modulation 
of nAChR function is another strategy.  However this requires a solid understanding of the 
functional relationship between the receptor and peptide as Aβ levels increase and different 
conformations of the peptide accumulate with disease progression.  Clearly, while great strides 
have been made in understanding the α7 nAChR – Aβ interaction in recent years, the likely 
complex nature of this relationship as AD progresses and soluble Aβ acquires additional 
aggregation conformers demands that much has yet to be understood before emphatically 
stating what the best α7 nAChR therapeutic strategy is for AD.   
 α7 nAChR – Aβ interaction.  However, as AD progresses 
and soluble Aβ acquires pathological concentrations and conformations, it might be useful to 
develop ways in which to interrupt specific α7 nAChR – Aβ interactions, especially if this 
interaction antagonizes receptor function or is involved in accumulating intracellular Aβ.  As is 
being currently pursued, targeting Aβ directly with immunotherapy is one appraoch.   
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FIGURE LEGENDS 
Figure 1.  Summary of the signal transduction consequences of Aβ activation of α7 nAChRs.  
Aβ1-42 acting through α7 nAChRs activates PKA downstream of ERK MAPK PI3K (and Akt) is an 
intermediary between α7 nAChR activation and ERK MAPK phosphorylation since LY294002 
blocked ERK MAPK activation following Aβ1-42.    ERK MAPK activation leads to p90 Rsk and CREB 
phosphorylation; Aβ1-42-induced p90 Rsk phosphorylation is carried out by both ERK and PKA 
since U0126 completely obliterated p90 Rsk phosphorylation and H-89 partially reduced it.   
Adapted from [43, 55, 64, 81].  
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